Skip to main content

Table 1 Histopathologic features of breast cancer xenografts and genomic correlation between primary tumor and xenograft

From: Molecular profiling of patient-derived breast cancer xenografts

Tumor xenograft

Phenotype (IHC) Patient/xenograft

Histology

Pearson's correlation coefficient

HBCx-3

ER+/ER+

IDC

0.76

HBCx-5

HER2+/HER2+

IDC

0.35

HBCx-6

TN/TN

IDC

0.60

HBCx-7

TN/TN

ILC

0.23

HBCx-8

TN/TN

IDC

0.82

HBCx-10

TN/TN

IDC

0.57

HBCx-11

TN/TN

IDC

0.65

HBCx-12A

TN/TN

IDC

0.66

HBCx-13A

HER2+/HER2+

IDC

0.86

HBCx-15

TN/TN

IDC

0.57

HBCx-16

TN/TN

IDC

0.46

HBCx-17

TN/TN

IDC

0.39

HBCx-20

ER+/ER+

IDC

0.87

HBCx-21

ER+PR+/ER+PR+

IDC

0.86

HBCx-22

ER+ PR+/ER+PR+

IDC

0.68

HBCx-23

TN/TN

IDC

0.80

HBCx-24

TN/TN

IDC

0.77

HBCx-31

TN/TN

IDC

0.86

  1. ER, estrogen receptor; HBC, human breast cancer; HBC-n, HBC primary tumor n; HBCx-n, HBC xenograft tumor n; HER, human epidermal growth factor receptor; IDC, invasive ductal carcinoma; IHC, immunohistochemistry; ILC; invasive lobular carcinoma; PR, progesterone receptor; TN, triple-negative. List of xenografts used in the study according to the breast cancer subtype. Expression of HER2; ER and PR was determined by IHC. Pearson's correlation coefficients between pairs of patient tumors and xenografts were calculated between the clone status (Gain, Normal, Loss) of the same probe.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us